Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TG103 Monotherapy in Type 2 Diabetes Mellitus
NCT06258148Phase 3Completed
- Sponsor
- CSPC Baike Biopharmaceutical
- Start
- Apr 2024
- Primary completion
- Jan 2026
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 3 trial of GX-G6 in type 2 diabetes mellitus (T2DM), sponsored by CSPC Baike Biopharmaceutical. Started Apr 2024; status: completed.
02
Drugs
GX-G6
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06258148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06258148.